Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ628630,50,16
KB768771-0,77
PKN78,478,48-3,54
Msft-0,56
Nokia4,3364,3515-0,90
IBM-1,70
Daimler AG76,9877,01-3,00
PFE-1,70
19.06.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.06.2021
Recordati (RECI.MI, Milan)
Závěr k 18.6.2021 Změna (%) Změna (EUR) Objem obchodů (EUR)
48,17 -0,68 -0,33 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.06.2021
Popis společnosti
Obecné informace
Název společnostiRecordati Industria Chimica e Farma SpA
TickerREC
TickerRECNC
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RICRECI.MI
ISINIT0003828271
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 4 362
Akcie v oběhu k 31.03.2021 206 225 973
MěnaEUR
Kontaktní informace
UliceVia M. Civitali, 1
MěstoMILANO
PSČ20148
ZeměItaly
Kontatní osoba 
Funkce kontaktní osoby 
Telefon3 902 487 871
Fax390240073747

Business Summary: Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Financial Summary: BRIEF: For the three months ended 31 March 2021, RecordatiIndustria Chimica e Farma SpA revenues decreased 10% toEUR384.8M. Net income decreased 19% to EUR89.9M. Revenuesreflect Specialty & Primary care segment decrease of 15% toEUR299.9M, Russia segment decrease of 52% to EUR17.1M,Italy segment decrease of 10% to EUR72.3M, Turkey segmentdecrease of 27% to EUR20.2M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007All Other Miscellaneous Food Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997All Other Miscellaneous Food Manufacturing
SICPharmaceutical Preparations
SICMedicinals And Botanicals
SICCommercial Physical Research
SICFood Preparations, Nec



  • Poslední aktualizace: 20.06.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorAndrea Recordati5005.02.2019
Vice Chairman of the BoardGuido Guidi-29.04.202029.04.2020
Group Chief Financial OfficerLuigi Corte-01.11.201901.11.2019
Executive Vice President - Rare Diseases Business UnitCorrado Castellucci-
Executive Vice President - Specialty and Primary Care Business UnitAlberto Martinez-
Executive Vice President of Group Industrial OperationsRoberto Teruzzi-
Senior Vice President - Group Human ResourcesGiuseppe Gualazzini6201.05.2014
Senior Vice President - Pharmaceutical Research and DevelopmentRaffaele Sabia-
Vice President - Corporate Development & LicensingGabriele Finzi-
Vice President - Corporate Legal CounselDaria Ghidoni-01.01.2011